Moderna has begun testing an mRNA flu vaccine in clinical trials, with the company announcing Wednesday that the first participants had been dosed in the Phase 1/2 study. The vaccine, mRNA-1010, is Moderna’s first seasonal flu vaccine candidate to enter clinical trials and will target influenza A H1n1, H3N2, and influenza B Yamagata and Victoria.
The company is aiming to enroll 180 participants ages 18 years and older in the trial, and eventually aims to study combination vaccines to target multiple respiratory viruses such as SARS-CoV-2 and RSV.
“We are pleased to have begun this Phase 1/2 study of mRNA-1010, our first mRNA seasonal flu vaccine candidate to enter the clinic,” Stephane Bancel, Moderna’s CEO, said in a news release. “Respiratory combination vaccines are an important pillar of our overall mRNA vaccine strategy. We believe that the advantages of mRNA vaccines include the ability to combine different antigens to protect against multiple viruses and the ability to rapidly respond to the evaluation of respiratory viruses, such as influenza, SARS-CoV-2 and RSV.”- READ MORE
Listen to the insightful Thomas Paine Podcast Below --